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ABSTRACT: The existence of nonannotated protein-coding human short open reading frames
(sORFs) has been revealed through the direct detection of their sORF-encoded polypeptide (SEP)
products. The discovery of novel SEPs increases the size of the genome and the proteome and
provides insights into the molecular biology of mammalian cells, such as the prevalent usage of non-
AUG start codons. Through modiﬁcations of the existing SEP-discovery workﬂow, we discover an
additional 195 SEPs in K562 cells and extend this methodology to identify novel human SEPs in
additional cell lines and human tissue for a ﬁnal tally of 237 new SEPs. These results continue to
expand the human genome and proteome and demonstrate that SEPs are a ubiquitous class of
nonannotated polypeptides that require further investigation.
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■ INTRODUCTION
Modern transcriptome proﬁling methods such as tiling arrays1
and whole transcriptome shotgun sequencing (RNA-Seq)2 have
revealed that a larger number of RNAs are produced from the
genome than previously thought.3−6 Furthermore, subsequent
analysis of these nonannotated transcripts has demonstrated
the existence of functional noncoding RNAs, such as long
intergenic noncoding RNAs (LINCs).7,8 The identiﬁcation of
additional RNAs also raises the possibility that there may also
exist additional nonannotated protein-coding RNAs. The
computational prediction of open reading frames (ORFs)
(i.e., protein-coding regions) relies on a number of stringent
criteria to avoid false discovery, such as a length cutoﬀ, AUG
start codon usage, and sequence conservation.9,10 These criteria
are not perfect, and several types of ORFs are often missed,
including ORFs that use non-AUG initiation codons as well as
short ORFs (sORFs) that fall below the typical length cutoﬀ of
a 100 codons (i.e., a 100 amino acid polypeptide).11,12 Frith
and colleagues, for example, utilized a new search algorithm to
reanalyze the mouse genome and predicted an additional 3000
protein-coding sORFs,13 which would correspond to an ∼10%
increase in the size of the mouse genome.14
More recently, direct experimental evidence of the existence
of non-AUG initiation sites and protein-coding sORFs has
begun to emerge. Ribosome proﬁling methods, which footprint
the location of the ribosome on RNAs to identify protein-
coding regions, revealed the existence of a number of
nonannotated protein-coding sORFs in the mouse genome.11
In these experiments, the addition of the drug cycloheximide
freezes the ribosome on start codons, and when cycloheximide
is used in combination with ribosome proﬁling, the start codons
of ORFs can also be identiﬁed.15 This analysis led to the
observation that while AUG is the most common codon used
(∼45% of the time), CUG and GUG are also frequently used,11
which contradicts the dogma that translation initiation is
restricted to AUG. Thus, ribosome proﬁling indicates that cells
often use non-AUG start codons and reveals the existence of
nonannotated protein-coding sORFs, both of which would
likely be missed by classical algorithms for predicting protein-
coding regions in the genome.
In addition to ribosome proﬁling, mass spectrometry (MS)
peptidomics and proteomics experiments have recently been
implemented in the discovery of sORF-encoded peptides
(SEPs).12,16 These MS experiments diﬀer from ribosome
proﬁling because they detect polypeptide generated from a
sORF and therefore validate the protein-coding potential of the
sORF by demonstrating the production of a stable protein
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product. Because of transcript ampliﬁcation and the number of
reads per sequencing, experiment ribosome proﬁling is more
sensitive and will identify the largest number of sORFs, but the
bias of MS toward more abundant proteins17 means that
peptidomics and proteomics will likely identify the most
abundant cellular SEPs, which might be the SEPs most likely to
be functional.
Slavoﬀ and colleagues developed and utilized a peptidomics-
based strategy for the detection of novel human SEPs.12 These
studies were based on initial observations by Yamamoto and
colleagues who identiﬁed four SEPs in K562 cells (deﬁned here
as fewer than 150 amino acids in length).18 To improve on
these results, Slavoﬀ and coworkers utilized next-generation
RNA sequencing (RNA-Seq) to identify all possible protein-
coding mRNA transcripts, including nonannotated transcripts
(i.e., transcripts that exist but are not in the NCBI RefSeq
database). The RNA-Seq data was translated into all possible
reading frames to create a database that should contain all of
the polypeptide sequences that could theoretically be produced
in the cell. Using this database, Slavoﬀ and colleagues identiﬁed
90 human SEPs in these K562 cells, and 86 of these SEPs were
novel.12 This work indicated that SEPs represent a large class of
nonannotated cellular polypeptides. Recent work from others
has also supported this conclusion, with Vanderperre and
colleagues having characterized 1259 nonannotated polypep-
tides,19 the largest number reported to date using an elegant
combination of bioinformatics and mass spectrometry.
Our goal here is to (1) determine whether we can identify a
workﬂow that provides the easiest route for SEP detection, (2)
determine whether SEPs exist in other cell lines, and (3)
determine whether we can ﬁnd SEPs in human tissues,
speciﬁcally a human tumor sample. Our results identify several
workﬂows for SEP discovery and demonstrate that SEPs are
ubiquitous and present in multiple cell lines and human tissues.
■ MATERIALS AND METHODS
Cell Culture
K562 cells were grown in RPMI1640 medium supplemented
with 10% FBS, penicillin and streptomycin at a density of (1 to
10) × 105 cells/mL. MCF10A cells were grown in MEGM
complete medium (Life Technologies), and MDAMB231 cells
were grown in DMEM medium supplemented with 10% FBS,
penicillin, and streptomycin. All cells were grown at 37 °C
under an atmosphere of 5% CO2.
Tissue Sample
Tissue was obtained from the Massachusetts General Hospital
(MGH) Department of Pathology as a deidentiﬁed sample.
This was done in accordance with all of the rules and
regulations of the Harvard IRB.
Peptidome Isolation from Cell Culture
Aliquots of K562, MCF10A, and MDAMB231 cells (2 × 108
cells per experiment) were placed in Falcon tubes, washed three
times with cold PBS, pelleted, and transferred into 1.5 mL
Protein LoBind tubes (Eppendorf). Boiling water (300 μL) was
directly added to the cell pellet, and the cells were boiled for an
additional 20 min. This step eliminates protease activity to
maintain the integrity of the peptidome for subsequent LC−
MS analysis. After the samples were cooled on ice, the cells
were sonicated on ice for 20 bursts at output level 2 with a 30%
duty cycle (Branson Soniﬁer 250; Ultrasonic Convertor).
Acetic acid was added to the cell lysate until the ﬁnal
concentration of acetic acid was 0.25% by volume. The sample
was then centrifuged at 14 000g for 20 min at 4 °C to
precipitate large proteins and reduce the complexity of the
sample. The supernatant was passed through a 30 kDa
molecular weight cutoﬀ (MWCO) ﬁlter, and the small proteins
and polypeptides were isolated in the ﬂow-through. An aliquot
of the ﬂow-through was taken for a BCA assay to measure the
protein concentration. The remaining sample was then
evaporated to dryness at low temperature in a SpeedVac and
used for LC−MS analysis.
In cases where PAGE analysis was used, this supernatant was
loaded onto a 16% Tricine gel (Novex, 1.0 mm) and run at 120
V for 80 min instead of being passed through an MWCO ﬁlter.
This gel was stained with Coomassie blue and then destained
using standard protocols. Dual Xtra Standards (Bio-Rad) was
used as the molecular-weight marker, and the gel was sectioned
below the 15 kDa marker to aﬀord three sections: 2−5, 5−10,
and 10−15 kDa. Each gel slice was placed in 1.5 mL Protein
LoBind tubes (Eppendorf) and washed with 1 mL of 50%
HPLC grade acetonitrile in water three times.
Peptidome Isolation from Tissue
Frozen human breast tumor sample (∼200 mg) was immersed
in boiling water (200 μL) for 10 min. This step denatures
proteins and eliminates proteolytic activity. The aqueous
fraction was collected and saved in a clean tube, and the tissue
was dounce-homogenized in 500 μL of ice-cold acetic acid
(0.5% v/v). The aqueous fraction and the homogenate were
combined and centrifuged at 20 000g for 20 min at 4 °C. The
supernatant was transferred to a new Lo-Bind tube and
evaporated to dryness at low temperature in a SpeedVac. The
dried sample was suspended in PBS and loading dye, followed
by separation in a 16% Tricine gel (Novex, 1.0 mm). The
excised gel bands (<15 kDa) were analyzed by LC−MS/MS, as
described later.
ERLIC Fractionation20,21
After trypsin digest the samples were dried in a speed vac and
suspended in ERLIC buﬀer A (90% acetonitrile 0.1% acetic
acid). Samples were then fractionated using an HPLC (Agilent
1200 HPLC) equipped with an ERLIC column (PolyWAX LP
Column, 200 × 2.1 mm, 5 μm, 300 Å (PolyLC)). Samples were
separated using a stepwise gradient with the following steps: 0−
5 min, 0% B; 5−15 min, 0−8% B; 15−45 min, 8−35% B; 45−
55 min, 35−75% B; 55−60 min, 75−100% B; 60−70 min,
100% B (A: 90% acetonitrile, 0.1% formic acid; B: 30%
acetonitrile, 0.1% formic acid). An automated fraction collector
was used to collect 25 equivalent fractions that were
concentrated then analyzed by LC−MS/MS.
LC−MS/MS Analysis
ERLIC samples were digested prior to ERLIC and did not
require any additional sample PREPL prior to LC−MS. Gel
slices from PAGE separation were extracted and then digested
with trypsin overnight. The resulting peptide mixture was
separated from any residual gel slices and analyzed on an
Orbitrap Velos hybrid ion trap mass spectrometer (Thermo
Fisher Scientiﬁc). Regions between 395 and 1600 m/z ions
were collected at 60K resolving power for the MS1, and these
data were used to trigger MS/MS in the ion trap for the top 20
ions in the MS1 (i.e., top 20 experiment). Active dynamic
exclusion of 500 ions for 90 s was used throughout the LC−
MS/MS method. Samples were trapped for 15 min with ﬂow
rate of 2 μL/min on a trapping column 100 μm ID packed for 5
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cm in-house with 5 μm Magic C18 AQ beads (Waters) and
eluted onto 20 cm × 75 μm ID analytical column (New
Objective) packed in-house with 3 μm Magic C18 AQ beads
(Waters). Peptides were eluted with 300 nL ﬂow rate using a
NanoAcquity pump (Waters) using a binary gradient of 2−32%
B over 90 min (A: 0.1% formic acid in water; B: 0.1% formic
acid in acetonitrile).
Data Processing
The SEQUEST algorithm22,23 was used to analyze the acquired
MS/MS spectra using a database derived from three-frame
translation from the RNA-Seq data for that cell line. RNA-Seq
data from K562, MCF10A, or MDAMB231 cell lines were
assembled into a transcriptome using Cuﬄinks24 and then
translated in three (forward) frames in silico. The search against
this database was performed using the following parameters:
variable modiﬁcations, oxidation (Met), N-acetylation, semi-
tryptic requirement, two maximum missed cleavages, precursor
mass tolerance of 20 ppm, and fragment mass tolerance of 0.7
Da. Search results were ﬁltered such that the estimated false
discovery rate of the remaining results was at 1%. For this
purpose the Sf score of greater than 0.7 was the required with a
mass accuracy of <3.5 ppm. After analysis, the data were ﬁltered
based on a combination of the preliminary score, the cross-
correlation, and the diﬀerential between the scores for the
highest scoring protein and the second highest scoring protein.
A list of peptides that passed the search criteria was then
searched against the Uniprot human (SwissProt) protein
database using a string-searching algorithm. Peptides found to
be identical and to overlap with part of annotated proteins were
eliminated from the list. The remaining peptides were then
searched one more time against nonredundant human protein
sequences using the Basic Local Alignment Search Tool
(BLAST).25,26 Peptides that were identical or diﬀerent by one
amino acid from the nearest protein match were discarded.
Peptides with more than two missed cleavages were also
removed at this point. The ﬁnal list of peptides, candidate SEPs,
were searched against Human Reference (RefSeq) RNA
sequences using BLAST to assess their location relative to
the annotated transcripts, which can be categorized into
5′UTR, 3′UTR, CDS, and noncoding. If the peptides had no
match in the RefSeq RNA sequences, then they were derived
from RNAs that were present in the RNA-Seq data that had not
been annotated in RefSeq (i.e., nonannotated RNAs).
RNA-Seq Library Preparation and Transcriptome Assembly
Total RNA (3000 ng) was puriﬁed from MCF10A and
MDAMB231 cell lines using RNeasy Kit (QIAGEN) according
to the instructions provided by the manufacturer. cDNA
libraries with paired-end, indexed adapters were created using
the Illumina TruSeq RNA sample prep kit. Two libraries were
pooled and sequenced on a single lane of a HiSeq2000
machine. RNA-Seq reads were aligned to the human genome
(hg19) using TopHat (version V2.0.4), and transcriptome
assembly was performed using Cuﬄinks (version V2.0.2).24
Skyline Targeted MRM LC−MS/MS Peptidomics
Sequences for SEPs were submitted in FASTA format to
Skyline (version 2.1.0.4936)27 for analysis. The goal was to
identify peptides from these sequences that are most amenable
for targeted proteomics using multiple-reaction monitoring
(MRM). Skyline predicted transitions for each peptide, and we
used all of transitions in a targeted MRM experiment to identify
the presence or absence of the peptide. We must detect at least
three transitions for a given peptide to determine that it is
present in the sample. The output from Skyline is imported
directly into a targeted method for analysis with a TSQ
Quantum Ultra triple stage quadrupole mass spectrometer (i.e.,
a triple quad (QQQ), Thermo Fisher Scientiﬁc). Peptide
samples were analyzed using the TSQ with a 90 min gradient
and targeted MRM tandem mass spectrometry using the
aforementioned Skyline method. Samples were trapped for 15
min with ﬂow rate of 2 μL/min on a trapping column 100 μm
ID packed for 5 cm in-house with 5 μm Magic C18 AQ beads
(Waters) and eluted with a gradient to 20 cm × 75 μm ID
analytical column (New Objective) packed in-house with 3 μm
Magic C18 AQ beads (Waters). Peptides were eluted with 300
nL ﬂow rate using a NanoAcquity pump (Waters) using a
binary gradient of 2−32% B over 180 min (A: 0.1% formic acid
in water; B: 0.1% formic acid in acetonitrile).
■ RESULTS AND DISCUSSION
Impact of Diﬀerent Workﬂows on SEP Discovery
Our ﬁrst goal was to determine whether changes to the
reported SEP-discovery workﬂow would lead to the identi-
ﬁcation of additional SEPs in K562 cells, and whether any
particular workﬂow is superior to others. In the reported
workﬂow,12 SEPs are separated from larger proteins with a 30
kDa molecular weight cutoﬀ (MWCO) ﬁlter, and the ≤30 kDa
fraction then undergoes electrostatic repulsion hydrophilic
Figure 1.Workﬂows tested in the discovery of novel human SEPs. (A) Schematic of the four diﬀerent SEP discovery workﬂows used: MWCO+LC−
MS; MWCO+ERLIC+LC−MS; PAGE+ERLIC+LC−MS; and PAGE+LC−MS. The K562 peptidome is separated by size using a 30 kDa MWCO
ﬁlter (MWCO) or polyacrylamide gel electrophoresis (PAGE) and then analyzed directly by LC−MS (ﬁrst and last lane) or fractionated by ERLIC
prior to LC−MS analysis (middle lanes). (B) Number of total SEP and novel SEPs identiﬁed in K562 cells using each of the four diﬀerent SEP
discovery workﬂows.
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interaction chromatography (ERLIC),20,21 followed by LC−
MS/MS (Figure 1A). This workﬂow led to the identiﬁcation of
90 SEPs, 86 of which were novel, in the commonly used K562
leukemia cell line.12 We refer to this workﬂow as MWCO
+ERLIC+LC−MS/MS. More recently (2013), Vanderperre
and colleagues have identiﬁed 1259 nonannotated polypep-
tides.19 Below, total SEPs refer to the total number of SEPs
discovered and novel SEPs refer to any SEPs from these groups
that were not identiﬁed in the Slavoﬀ et al. or Vanderperre et al.
manuscripts.
Three additional workﬂows were tested here: MWCO+LC−
MS/MS, PAGE+ERLIC+LC−MS/MS, and PAGE+LC−MS/
MS. In these workﬂows, MWCO indicates fractionation using a
30 kDa MWCO ﬁlter, while PAGE refers to molecular weight
fractionation using a 16% Tricine polyacrylamide gel, where the
region between 2 and 15 kDa is analyzed by LC−MS/MS. We
used K562 cells in these experiments. All of these workﬂows led
to the discovery of novel human SEPs, though the number of
SEPs, and the ease of the diﬀerent methods varied.
We began by comparing the MWCO+LC−MS/MS and the
PAGE+LC−MS/MS workﬂows. These workﬂows diﬀer in their
approach to peptidome isolation by using a 30 kDa MWCO
ﬁlter or the excising the 2−15 kDa portion of a 16% tricine gel.
After separation, the ≤30 kDa fraction is treated with trypsin
and then analyzed by LC−MS/MS. The 2−15 kDa gel slice
undergoes an in-gel trypsin digest, followed by LC−MS/MS
analysis. SEPs are identiﬁed using a custom K562 database
generated from RNA-Seq data that will account for
polypeptides produced from previously nonannotated protein-
coding sORFs. We identiﬁed 13 SEPs using the MWCO+LC−
MS/MS workﬂow with a single LC−MS/MS run. Of these 13
SEPs, six were novel, while seven were previously identiﬁed
(Figure 1B). In comparison, the PAGE+LC−MS/MS workﬂow
identiﬁed 19 SEPs, with seven of these being novel. These
results indicate that both MWCO and PAGE fractionation are
able to identify similar number of total SEPs (13 vs 19) per
LC−MS/MS run (Figure 1B). None of the novel SEPs
discovered by these two methods overlapped, resulting in the
discovery of an additional 13 human SEPs (six from MWCO
and seven from PAGE).
Next, we analyzed the K562 sample by PAGE+ERLIC+LC−
MS/MS (Figure 1A). In this approach, we subject the sample
to ERLIC after an in-gel trypsin digestion. The ERLIC
fractionated samples are then analyzed by LC−MS/MS and
new SEPs identiﬁed by analysis of the K562 database. This
analysis led to the identiﬁcation of 94 SEPs and 80 novel SEPs
(Figure 1B). Thus, the two workﬂows that utilize ERLIC
identify 90−94 SEPs per run, while workﬂows without ERLIC
identiﬁed 13−19 SEPs per run. As expected, increased
fractionation results in better coverage, and there is no
substantial diﬀerence between diﬀerent methods of peptidome
size fractionation (i.e., PAGE or MWCO).
Biological and Technical Replicates Increase the Number
of SEPs Discovered
The preliminary data revealed that there is little overlap
between the diﬀerent workﬂows. We hypothesize that the low
natural abundance of SEPs and shotgun peptidomics, which is
inherently stochastic,17 results in the low overlap among
samples. Indeed, the Yates lab has demonstrated that in
complex mixtures data-dependent data acquisition does not
completely sample all peptides in a sample and therefore does
not provide information on all ions.17 On the basis of models of
this process, they determined that for yeast-cell-soluble lysate
10 replicates are required to achieve 95% saturation of the
proteome.17 In addition, most SEPs are short (<100 amino
acids) such that they do not generate many tryptic peptides
that can be used to identify a SEP. In most cases, we detect only
a single peptide for each SEP identiﬁed, and if this peptide is
missed due to ineﬃcient ionization or low abundance then the
entire SEP and sORF is overlooked. Together, these factors
contribute to the variable detection of SEPs. If SEP detection
was stochastic, then biological and technical replicates would be
expected to show little overlap in the SEPs identiﬁed per LC−
MS/MS run, but each replicate analysis would yield additional
SEPs.
We repeated the PAGE+LC−MS/MS for three additional
K562 samples for a total of four biological replicates (which
includes the sample from Figure 1). An average of 22 SEPs
were detected per run with a range between 11 and 37 SEPs in
each sample (Figure 2A). Of the 87 total SEPs identiﬁed, 26
overlapped with previously detected SEPs and 61 were novel,
for an average of 15 new human SEPs per run. Many of the
novel SEPs were only identiﬁed in a single sample. These
results bring the total number of novel SEPs detected here to
147 (80 from PAGE+ERLIC+LC−MS (Figure 1), 6 from
MWCO + LC−MS (Figure 1), and 61 from four PAGE+LC−
MS biological replicates (Figure 2)). The lack of overlap
between samples is consistent with our previous observations
Figure 2. Biological and technical replicates lead to the discovery of novel SEPs. (A) Number of SEPs detected in four biological replicates of K562
cells. Each of these samples was analyzed using the PAGE+LC−MS SEP discovery workﬂow. For each replicate, the detected SEPs include the total
number of SEPs identiﬁed as well as the novel SEPs that were characterized for the ﬁrst time. (B) Three technical replicates of biological replicate #4
from panel A were performed using the PAGE+LC−MS workﬂow with K562 peptidome. The total number of SEPs detected in each run (black),
nonoverlapping SEPs (gray; SEPs that were not present in either of the other two technical replicates), and novel SEPs (light gray; SEPs that were
not detected in any other analysis).
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and supports the idea that SEP detection is variable, as
predicted from proteomics studies.17
Next, we tested the impact of performing technical replicates.
We analyzed biological replicate #4 (Figure 2A) − where we
identiﬁed 37 total SEPs in the ﬁrst run − two more times to
provide a total of three technical replicates. In the three runs,
we identiﬁed 37, 29, and 29 SEPs in each run (Figure 2B). Of
the 29 SEPs identiﬁed in the second run, 25 were not detected
in the ﬁrst run (i.e., nonoverlapping SEPs), and of the 29
detected in the third run, 15 were not detected in the ﬁrst or
second runs (Figure 2B). The number of novel SEPs identiﬁed
per run decreased from 28 to 12 as more runs were performed,
but there was still a substantial number of novel SEPs
discovered even after three technical replicates. This result
aﬃrms the hypothesis that SEP detection is stochastic and
demonstrates the value in performing biological or technical
replicates to increase the number of SEPs discovered.
Additionally, we also performed ﬁve more technical replicates
(using biological replicate #3 from Figure 2A) and detected 48
SEPs (with 32 of these being novel SEPs) (Supporting
Information, Figure 1). At this point, we had identiﬁed a
total of 195 novel SEPs (i.e., not identiﬁed in Slavoﬀ et al. or
Vanderperre et al.) in K562 cells through a combination of
diﬀerent workﬂows and biological and technical replicates.
Three to four biological/technical replicates matched the
total number and novel SEPs identiﬁed through an ERLIC
fractionation; however, we analyzed a total of 25 ERLIC
fractions by LC−MS/MS. Thus, it seems more eﬃcient to
perform multiple technical and or biological replicates when
wanting to identify more SEPs, as predicted from similar
conclusions made with data-dependent proteomics experi-
ments.17 Finally, a handful of SEPs was detected among
biological or technical replicates repeatedly, such as ASNSD1-
SEP and CIR1-SEP. ASNSD1-SEP is the most frequently SEP
and therefore is likely to have high cellular concentration and
stability. ASNSD1-SEP also shows an unmistakable evolu-
tionary signature of protein coding regions (Supporting
Information, Figure 2), as measured across 29 eutherian
mammals by PhyloCSF.28 In total, 195 novel SEPs represent a
>200% increase from the previous study and also the largest
number of SEPs ever reported from a single cell line.
Using Targeted LC−MS/MS to Rapidly Validate Novel SEPs
In the majority of cases, a single peptide is used to identify an
SEP. Analysis of our data showed that only 7 out of the 195
novel SEPs had more than one unique peptide to support the
protein-coding potential of the sORF. To obtain additional data
to support the identiﬁcation of a novel protein-coding sORF,
we previously relied on molecular biology.12 We cloned the
candidate protein-coding sORFs and tested whether they
produce SEPs in mammalian cells to ensure that the newly
identiﬁed sORF actually coded for proteins. While successful,
this approach is time-consuming and does not provide the
necessary throughput to validate large numbers of SEPs easily.
We decided to use mass spectrometry instead of molecular
biology to increase the throughput and provide more evidence
of the endogenous detection of SEPs. Speciﬁcally, our aim was
to use targeted MRM LC−MS/MS to characterize additional
peptides from sORFs. This approach would aﬀord more than
one peptide from the sORF and in doing so would provide the
necessary data to validate the sORF and should increase
throughput.
Skyline, a program designed to identify the best tryptic
peptides from an ORF for targeted MRM experiments,27 was
used to deﬁne the MRM transitions for peptides derived from
105 SEPs. These SEPs included the 81 from the PAGE+ERLIC
+LC−MS and 7 from MCWO+LC−MS (Figure 1) as well as
17 SEPs from the biological replicates #1 and #2, which were
identiﬁed by PAGE+LC−MS (Figure 2), for a total of 105
SEPs. Trypsin digestion of these 105 SEPs resulted in 224
tryptic peptides, and over 700 transitions were predicted by
Skyline and monitored by targeted MRM LC−MS/MS. The
total number of SEPs was capped at 105 in this targeted MRM
LC−MS experiment due to the total number of MRM
transitions that could be easily monitored per run. This
experiment conﬁrmed the presence of 62 peptides out of the
possible 224 (27%), and the identiﬁcation of these peptides
resulted in having at least two peptides identiﬁed for 36 out of
the 105 SEPs (34%) (Supporting Information, Table S1).
Skyline analysis of PRR3-SEP (Figure 3), for example,
identiﬁed MRM transitions for four tryptic peptides, and a
targeted LC−MS/MS using these transitions identiﬁed the
existence of two out of four of these peptides (Supporting
Information, Figure 3 for MS/MS of PRR3-SEP peptide that
we detected). Along, with the PRR3-SEP peptide identiﬁed
during shotgun peptidomics, we now have a total of three
peptides identiﬁed from the PRR3-SEP, which provides the
necessary conﬁrmation that the PRR3 sORF is protein-coding.
Using molecular biology and peptide synthesis we had
previously validated 17 out of 86 novel SEPs (20%) by
expression or coelution over several weeks.12 Here we validated
36 out of a 105 SEPs (34%) by identifying a second peptide in
approximately 1 week. Out of these 36 validated SEPs, 32 were
novel. Thus, using Skyline27 to deﬁne MRM transitions for SEP
tryptic peptides and targeted MRM LC−MS/MS to validate
SEPs provides a much more facile and eﬃcient approach.
Overview of the 195 Newly Identiﬁed SEPs
We analyzed the length distribution, codon usage, and source of
RNA to determine whether the 195 newly identiﬁed SEPs in
K562 cells diﬀer substantially from the 86 SEPs we had
previously identiﬁed.12 The length distribution for the SEPs was
Figure 3. Validating SEPs with targeted mass spectrometry. Analysis of
PRR3-SEP by Skyline and subsequent MRM targeted LC−MS
identiﬁes additional peptides from this SEP. The tryptic peptide
(blue box) that was detected in the original shotgun proteomics
experiment led to the initial identiﬁcation of the PRR3-SEP. To
identify additional peptides from PRR3-SEP, we used Skyline to
predict MRM transitions for four tryptic peptides from PRR3-SEP,
and this information is fed into a targeted LC−MS experiment. This
experiment identiﬁed peptides for two out of the four peptides and
provided an additional two peptides (red and purple boxes) to validate
this PRR3-SEP.
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determined by using AUG-to-stop or upstream stop-to-stop
(i.e., distance between two in frame stop codons that
encompass the sORF). We did not try to predict alternative
start codons for the length distribution because we did not want
to bias the analysis toward shorter lengths. The SEPs range
between 8 and 134 amino acids long, with the majority (>90%)
of new SEPs being <100 amino acids long (Figure 4A).
We assigned initiation codons to sORFs using a simple set of
criteria. An upstream in-frame AUG was assumed to be the
start if present; otherwise, the initiation codon was assigned to
an in-frame near-cognate codon (NCC), which diﬀers from
AUG by a single base. NCCs were commonly found in
ribosome-proﬁling experiments11 and our previous SEP
discovery eﬀort,12 so this result is consistent with what has
already been observed. If neither of these criteria was met, then
no start codon was assigned. Many of these SEPs (∼70%) do
not appear to initiate with an AUG codon (Figure 4B).
Lastly, we tried to account for the RNAs that are responsible
for producing these SEPs. First, we determined the RNAs in
the RefSeq database that produce SEPs, and we refer to this
pool of RNAs as “annotated RNAs”. These RefSeq RNAs are
primarily mRNAs, which already contain a protein-coding
ORF. Slightly over a quarter of all SEPs we discovered, 47 in
total, are derived from RefSeq RNAs (Figure 4C) A breakdown
of the distribution of these SEPs on the RNAs reveals that a
majority are found on the 3′-UTR. We counted sORFs in the
3′-UTR only if there was an additional stop codon between the
start of the sORF and the stop codon of the upstream ORF and
to avoid identifying read-through products.29,30 In addition, we
did not identify any splice acceptor sites at the 5′-end of the 3′-
UTR sORFs,31 indicating that these were not alternative exons.
SEPs are also produced from sORFs regions that are frame-
shifted within the coding sequence (CDS) of the longer ORF.
These SEPs are likely produced from RNA splice forms that
can only translate the sORF to produce the SEP because there
is no plausible mechanism to explain the production of the
ORF and sORF from the same mRNA.12 Because splice forms
are diﬃcult to distinguish by RNA-Seq, further experimentation
is necessary to validate that some SEPs are produced from a
splice form of a known annotated RNA. The remaining sORFs
are found in the 5′-UTR of RNAs (two SEPs in this study are
generated from 5′-UTR of RefSeq annotated RNAs, and these
SEPs were detected previously in the study by Vanderperre et
al.), noncoding RNAs, and antisense RNAs (i.e., reverse-
complement of known RNAs), which are produced at sites of
transcription.32,33 The discovery of a protein-coding sequence
within a RNA that is annotated as noncoding reveals a
weakness in common algorithms that assign protein-coding
genes.9 The small number of sORFs in the 5′-UTR of RefSeq
RNAs is the biggest diﬀerence between this set of SEPs and the
previously reported set,12 where the majority of RefSeq sORFs
we found were in the 5′-UTR. There could be several reasons
for this, including the possibility that sORFs in the 5′-UTR
produce the most abundant SEPs and therefore we and others
already discovered the majority of them. Transcripts that are
not part of the RefSeq database are considered to be “non-
annotated”. We identiﬁed 148 SEPs that were generated from
these nonannotated transcripts in the K562 RNA-seq database.
Thus, there are still mRNAs and protein-coding genes that
remain to be discovered.
We also measured the lengths, initiation codon usage, and
RNA source for the 36 MRM-validated SEPs from this set of
195 SEPs to determine whether MRM targeting is enriching for
a particular class of SEPs. We ﬁnd a similar distribution for SEP
length, start codon usage, and SEP mRNA RefSeq annotation
for the 36 MRM-validated SEPs (Supporting Information,
Figure 4) as we do for the 195 SEPs (Figure 3), indicating that
no bias is introduced during the targeted MRM experiment and
further supporting the use of Skyline-targeted MRM as a
general, rapid approach for the high-throughput validation of
SEPs.
SEPs Are Found in Additional Cell Lines and Some Show a
Cell-Speciﬁc Distribution
To ascertain whether SEPs are found in other cell lines and
whether some SEPs are speciﬁc to certain cell lines, we proﬁled
the MCF10A and MDAMB231 cell lines. These are breast
cancer cell lines that diﬀer in their invasiveness, with
MDAMB231 being invasive.34 Invasiveness is a measure of
the ability of a cell line to tunnel through a matrix in cell culture
and is thought to model the aggressiveness of the cancer cell
line.35
Figure 4. Overview of 195 novel SEPs identiﬁed in K562 cells. (A)
Length of each SEP was determined using a deﬁned set of criteria (see
Methods), and the length distribution reveals that the majority
(>90%) of SEPs discovered are between 8 and 100 amino acids. (B)
SEPs utilize AUG, near cognate codons (i.e., one base away from
AUG), and unknown codons to initiate translations. (C) SEPs are
primarily derived from nonannoated RNAs (i.e., not found in RefSeq
database), but RefSeq RNAs do account for the production of 24% of
these SEPs. For the RefSeq-RNAs, the sORFs are found on coding
RNAs at the 3′-UTR and CDS and on noncoding RNAs such as
antisense RNAs and noncoding RNAs.
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We obtained RNA-Seq data for these cell lines, assembled
these data into a transcriptome, and then translated these
sequences into a custom protein database. Analysis of MCF10A
and MDAMB231 by PAGE+LC−MS/MS led to the
identiﬁcation of 12 and 17 SEPs, respectively (Figure 5A and
Supporting Information, Figure 5). Analysis of these SEPs by
Skyline followed by a targeted MRM LC−MS/MS experiment
validated 14 of these SEPs (out of 29) − 9 in the MCF10A cell
line and 5 in the MDAMB231 cell line (Figure 5B).
These 14 SEPs were targeted MRM LC−MS in both cell
lines (MCF10A and MDAMB231) to determine whether any
of these SEPs are speciﬁc to either cell line. Out of the 14 SEPs
targeted, 12 are present in the MCF10A and MDAMB231 cell
lines, while two SEPs are found only in the MDAMB231
sample (Figure 5C). Together, these experiments demonstrate
that SEPs are found in additional (i.e., not K562) cell lines and
that some SEPs might be speciﬁc to particular cell lines.
SEPs Are Present in Human Tissue
To determine whether we could ﬁnd SEPs in human tissue, we
used the protein database generated from K562 cells (this was
the largest database we had) and analyzed a human breast
cancer tissue biopsy by PAGE+LC−MS/MS. This analysis
yielded 25 SEPs, 22 of which were novel and 3 were also found
in K562 cells. One SEP found on the MYBL2 RNA (MYBL2-
SEP) was found in every sample we analyzed (tumor sample,
MCF10A, MDAMB231, and K562 cell lines), indicating that
some SEPs are ubiquitous and may serve broad biological roles.
These newly identiﬁed 25 tissue-derived SEPs (tdSEPs) were
then analyzed to estimate the lengths of the sORFs, their
initiation codon usage, and whether the RNAs that produce
these SEPs were annotated or nonannotated. The SEP length
for these tdSEPs varied between 15 and 138 amino acids, the
percentage of AUG usage was 24%, and most were derived
from nonannotated RNAs (80%), which is consistent with data
obtained from cell lines (i.e., K562, MCF10A, and
MDAMB231) (Figure 6). These data support the idea that
SEPs are ubiquitous and found in tissues as well, which further
enhances the interest in this class of polypeptides.
■ CONCLUSIONS
We tested several parameters for our SEP discovery workﬂow
and determined that running replicates (technical/biological) is
the most eﬃcient way to detect more SEPs. In total, we
describe the discovery of an additional 237 human SEPs (Table
1), demonstrating the prevalence of this class of polypeptides.
With an increasing number of SEPs discovered through our
shotgun proﬁling it became obvious that our previous approach
for validation would not suﬃce and therefore we utilized a
targeted MRM LC−MS/MS approach that relies on Skyline27
to rapidly identify multiple peptides from a single SEP/sORF.
Through the analysis of additional cell lines and a tumor biopsy,
we also ﬁnd that SEPs are ubiquitous and that at least some
SEPs are speciﬁc to a cell line. This eﬀort provides the
necessary evidence for us to begin to start large-scale SEP
proﬁling experiments. These experiments could be done by
Figure 5. SEP derived from MCF10A and MDAMB231 cell lines. (A) Steps in the discovery and validation of SEPs from these cell lines. (B) Total
of nine and ﬁve SEPs were validated using MRM in the MCF10A and MDAMB231 cell lines, respectively. (C) These 14 validated SEPs were
targeted in MCF10A and MDAMB231, while 12 SEPs found in both cell lines, two SEPs, TASP1-SEP, and CAMD8-SEP, were speciﬁc to the
MDAMB231 cell line.
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diﬀerentially proﬁling SEPs in disease models to identify SEPs
that might cause disease or can serve as a biomarker.
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(14) Gueńet, J. L. The mouse genome. Genome Res. 2005, 15, 1729.
(15) Ingolia, N. T.; Brar, G. A.; Rouskin, S.; McGeachy, A. M.;
Weissman, J. S. The ribosome profiling strategy for monitoring
translation in vivo by deep sequencing of ribosome-protected mRNA
fragments. Nat. Protoc. 2012, 7, 1534.
(16) Schwaid, A. G.; Shannon, D. A.; Ma, J.; Slavoff, S. A.; Levin, J.
Z.; Weerapana, E.; Saghatelian, A. Chemoproteomic discovery of
cysteine-containing human sORFs. J. Am. Chem. Soc. 2013, 135,
16750−16753.
(17) Liu, H.; Sadygov, R. G.; Yates, J. R. A model for random
sampling and estimation of relative protein abundance in shotgun
proteomics. Anal. Chem. 2004, 76, 4193.
(18) Oyama, M.; Kozuka-Hata, H.; Suzuki, Y.; Semba, K.;
Yamamoto, T.; Sugano, S. Diversity of translation start sites may
define increased complexity of the human short ORFeome. Mol. Cell.
Proteomics 2007, 6, 1000.
(19) Vanderperre, B.; Lucier, J.-F.; Bissonnette, C.; Motard, J.;
Tremblay, G.; Vanderperre, S.; Wisztorski, M.; Salzet, M.; Boisvert, F.-
M.; Roucou, X. Direct detection of alternative open reading frames
translation products in human significantly expands the proteome.
PloS One 2013, 8, e70698.
(20) Hao, P.; Zhang, H.; Sze, S. K. Application of electrostatic
repulsion hydrophilic interaction chromatography to the character-
ization of proteome, glycoproteome, and phosphoproteome using
nano LC-MS/MS. Methods Mol. Biol. 2011, 790, 305.
(21) Hao, P.; Qian, J.; Dutta, B.; Cheow, E. S.; Sim, K. H.; Meng, W.;
Adav, S. S.; Alpert, A.; Sze, S. K. Enhanced separation and
characterization of deamidated peptides with RP-ERLIC-based
multidimensional chromatography coupled with tandem mass
spectrometry. J. Proteome Res. 2012, 11, 1804.
(22) Gatlin, C. L.; Eng, J. K.; Cross, S. T.; Detter, J. C.; Yates, J. R.
Automated identification of amino acid sequence variations in proteins
by HPLC/microspray tandem mass spectrometry. Anal. Chem. 2000,
72, 757.
(23) MacCoss, M. J.; Wu, C. C.; Yates, J. R. Probability-based
validation of protein identifications using a modified SEQUEST
algorithm. Anal. Chem. 2002, 74, 5593.
(24) Trapnell, C.; Roberts, A.; Goff, L.; Pertea, G.; Kim, D.; Kelley,
D. R.; Pimentel, H.; Salzberg, S. L.; Rinn, J. L.; Pachter, L. Differential
gene and transcript expression analysis of RNA-seq experiments with
TopHat and Cufflinks. Nat. Protoc. 2012, 7, 562.
(25) Altschul, S. F.; Gish, W.; Miller, W.; Myers, E. W.; Lipman, D. J.
Basic local alignment search tool. J. Mol. Biol. 1990, 215, 403.
(26) Altschul, S. F.; Madden, T. L.; Schaf̈fer, A. A.; Zhang, J.; Zhang,
Z.; Miller, W.; Lipman, D. J. Gapped BLAST and PSI-BLAST: a new
generation of protein database search programs. Nucleic Acids Res.
1997, 25, 3389.
(27) MacLean, B.; Tomazela, D. M.; Shulman, N.; Chambers, M.;
Finney, G. L.; Frewen, B.; Kern, R.; Tabb, D. L.; Liebler, D. C.;
MacCoss, M. J. Skyline: an open source document editor for creating
and analyzing targeted proteomics experiments. Bioinformatics 2010,
26, 966.
(28) Lin, M. F.; Jungreis, I.; Kellis, M. PhyloCSF: a comparative
genomics method to distinguish protein coding and non-coding
regions. Bioinformatics 2011, 27, i275.
(29) Chittum, H. S.; Lane, W. S.; Carlson, B. A.; Roller, P. P.; Lung,
F.-D. T.; Lee, B. J.; Hatfield, D. L. Rabbit β-globin is extended beyond
its UGA stop codon by multiple suppressions and translational reading
gaps. Biochemistry 1998, 37, 10866.
(30) Tork, S.; Hatin, I.; Rousset, J. P.; Fabret, C. The major 5′
determinant in stop codon read-through involves two adjacent
adenines. Nucleic Acids Res. 2004, 32, 415.
(31) Salzberg, S. L. A method for identifying splice sites and
translational start sites in eukaryotic mRNA. CABIOS, Comput. Appl.
Biosci. 1997, 13, 365.
(32) Gunning, P.; Leavitt, J.; Muscat, G.; Ng, S.-Y.; Kedes, L. A
human beta-actin expression vector system directs high-level
accumulation of antisense transcripts. Proc. Natl. Acad. Sci. 1987, 84,
4831.
(33) Katayama, S.; Tomaru, Y.; Kasukawa, T.; Waki, K.; Nakanishi,
M.; Nakamura, M.; Nishida, H.; Yap, C.; Suzuki, M.; Kawai, J.
Antisense transcription in the mammalian transcriptome. Science 2005,
309, 1564.
(34) Jessani, N.; Liu, Y.; Humphrey, M.; Cravatt, B. F. Enzyme
activity profiles of the secreted and membrane proteome that depict
cancer cell invasiveness. Proc. Natl. Acad. Sci. 2002, 99, 10335.
(35) Albini, A.; Iwamoto, Y.; Kleinman, H.; Martin, G.; Aaronson, S.;
Kozlowski, J.; McEwan, R. A rapid in vitro assay for quantitating the
invasive potential of tumor cells. Cancer Res. 1987, 47, 3239.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr401280w | J. Proteome Res. 2014, 13, 1757−17651765
